CytomX Therapeutics Inc (NAS:CTMX)
$ 1.02 0 (0%) Market Cap: 79.82 Mil Enterprise Value: -27.17 Mil PE Ratio: 6.00 PB Ratio: 0 GF Score: 52/100

CytomX Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 03:40PM GMT
Release Date Price: $9.23 (-36.08%)
Ashwani Verma
BofA Merrill Lynch, Research Division - Research Analyst

Good morning, everyone. This session is for CytomX. My name is Ash Verma, and I'm part of the [Smith Capitec and Spec Pharma] team here at Bank of America. And CytomX is a clinical stage biotech company with a focus on cancer immunotherapy. And with me today is Sean McCarthy, Chairman, President and CEO of CytomX. Over to you, Sean.

Sean A. McCarthy
CytomX Therapeutics, Inc. - Chairman, CEO & President

Great. Thank you very much, Ash, and good morning, everyone. Thanks for joining us today. It's a pleasure to be here to provide an update on our recent progress and future directions at CytomX. So moving to Slide 2, our forward-looking statements. I want to remind you that over the next 30 minutes or so, I will be making certain forward-looking statements, and I refer you to our safe harbor statement. Now this has been a very busy year for us at CytomX. We've had many achievements so far this year. And abstracts were, of course, released yesterday for several presentations at ASCO.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot